FLUTTER FF352 LS2 BLACK HELMET CRASH MOTORBIKE MOTORCYCLE FACE FULL PURPLE PINK Motorcycle Helmets


  1. Home
  2. FLUTTER FF352 LS2 BLACK HELMET CRASH MOTORBIKE MOTORCYCLE FACE FULL PURPLE PINK
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
LS2 FF352 FLUTTER BLACK PINK PURPLE FULL FACE MOTORCYCLE MOTORBIKE CRASH HELMET
Condition: New Gender: Men's, Women's, Boys' & Girls', Unisex Adult, Unisex Youth
Type: FULLFACE Model:

F352 FLUTTER

Manufacturer: LS2 Exact Colour: Black / Purple
Goggles/ Visor Included?: Visor Brand:

LS2

Helmet Type: FULL FACE Weight Range: 1200 - 1399 g
Bundled Items: Reflective Sticker(s) Style: Full Face
Features: ACU Approved, Fully Removable Interior, Hi-Vis/Reflective, Pinlock Ready, Quick Release Fastening, Scratch Resistant Visor Shell Construction: Thermo-Resin
Manufacturer Part Number:

FF352

Use: Motorcycle
Finish: Gloss Sharp Rating: 4 Star
Design: Graphic MPN:

FF352



published on tue nov 09 2021

FLUTTER FF352 LS2 BLACK HELMET CRASH MOTORBIKE MOTORCYCLE FACE FULL PURPLE PINK Motorcycle Helmets

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

FLUTTER FF352 LS2 BLACK HELMET CRASH MOTORBIKE MOTORCYCLE FACE FULL PURPLE PINK Motorcycle Helmets

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS